1. Desipramine increases cardiac parasympathetic activity via α 2 -adrenergic mechanism in rats
- Author
-
Atsunori Kamiya, Masafumi Fukumitsu, Masaru Sugimachi, Shuji Shimizu, Tsuyoshi Akiyama, and Toru Kawada
- Subjects
medicine.medical_specialty ,Endocrine and Autonomic Systems ,Chemistry ,medicine.medical_treatment ,Stimulation ,030204 cardiovascular system & hematology ,Pharmacology ,Vagotomy ,Peripheral ,Yohimbine ,Norepinephrine (medication) ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Endocrinology ,In vivo ,Desipramine ,Internal medicine ,medicine ,Neurology (clinical) ,human activities ,030217 neurology & neurosurgery ,Acetylcholine ,medicine.drug - Abstract
Desipramine (DMI) is a blocker of neuronal norepinephrine (NE) uptake transporter. Although intravenous DMI has been shown to cause centrally-mediated sympathoinhibition and peripheral NE accumulation, its parasympathetic effect remains to be elucidated. We hypothesized that intravenous DMI activates the cardiac vagal nerve via an α2-adrenergic mechanism. Using a cardiac microdialysis technique, changes in myocardial interstitial acetylcholine (ACh) levels in the left ventricular free wall in response to intravenous DMI (1mg·kg-1) were examined in anesthetized rats. In rats with intact vagi (n=7), intravenous DMI increased ACh from 1.67±0.43 to 2.48±0.66nM (P
- Published
- 2017
- Full Text
- View/download PDF